Evaluation of the serum testosterone to prostate‐specific antigen ratio as a predictor of prostate cancer risk

Abstract

ultrasonography-guided biopsy using a 10-core scheme, with an additional 1-8 cores according to prostate volume and patient age. The sT level was determined before the procedure using a chemiluminescent assay, and the ratio of sT to PSA (sT/PSA) was calculated after transforming sT measurements from ng/dL to ng/mL. The percentage free PSA (%fPSA) and PSA density were also included in this analysis. RESULTSThe overall cancer detection rate was 42.1%. The median sT level was 469 ng/dL in men with cancer and 499 ng/dL in those without ( P = 0.521). The median sT/PSA was 0.68 and 0.74, respectively ( P = 0.215). However, the median %fPSA was 14 in men with cancer and 17 in men without ( P < 0.001) and the median PSA density was 0.22 and 0.16, respectively ( P < 0.001). The multivariate analysis confirmed the independent predictive value only for %fPSA (odds ratio 0.94, 95% confidence interval 0.91-0.98) and PSA density (5.8, 3.42-19.8). CONCLUSIONThese results do not support the use of sT/ PSA for predicting the risk of prostate cancer and to increase the specificity of PSA.

Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy

“…Our data are in agreement with earlier reports failing to establish a positive relationship between circulating T levels and the development of PCa [12,13,21]. A recent meta-analysis did not find relationships between testosterone, calculated free testosterone, dihydrotestosterone, dehydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, oestradiol, and calculated free oestradiol [22].…”

“…The present study was performed in Barcelona, Spain. Interestingly, a very similar study was recently performed in a different area of Barcelona with a similar methodology and this study did not find a relationship between serum T and PCa [21]. Only a multicenter, prospective study with strictly defined indications and criteria for the diagnosis malignancy, preferably hormone levels determined in a single laboratory, ideally including sequential analysis over the course of time could resolve these contradictory results.…”

Investigative Clinical Study on Prostate Cancer Part II: On the Role of the Pretreatment Total PSA to Free Testosterone Ratio as a Marker Assessing Prostate Cancer Prognostic Groups after Radical Retropubic Prostatectomy

“…At the same time prostate cancer shows hormone dependence and biological activity by secreting PSA. A study failed to show the ratio of serum testosterone to PSA as a predictor of prostate cancer risk [26] . This study was completely different from our investigation.…”

Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness

“…30 This study, beyond assessing the TT as a possible risk factor for positive biopsy, analyzed the value of cardiovascular risk factors (MetS), clinical factors and testosterone values (LOH) together with the PSA (TT/PSA ratio) in the biopsy result. In the study of Morote et al TT/PSA ratio was similar in patients with and without PCa.…”